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SHORT COMMUNICATION
High prevalence of Clostridium difficile diarrhoea during intensive
chemotherapy for disseminated germ cell cancer
H. Nielsen, G. Daugaard, M. Tvede & B. Bruun
Departments ofClinical Microbiology and Oncology, Rigshopitalet, Copenhagen, Denmark.
Summary A prospective, consecutive study of the aetiology of treatment-associated diarrhoea was conducted
in 25 patients with disseminated germ cell cancer treated with intensive chemotherapy. Clostridium difficile was
isolated in 45% of the diarrhoea episodes, which makes this species the most important bacterial pathogen in
the development of clinically significant diarrhoea in this group of immunocompromised patients.
Patients with malignant diseases treated with cytotoxic
chemotherapy are an important group of immunocompro-
mised patients susceptible to opportunistic infections. Several
reports document that diarrhoea in such patients may be
associated with Clostridium difficile (Cudmore et al., 1982;
Morris et al., 1984; Miller & Koornhof, 1984; Rampling et
al., 1985; Heard et al., 1988). The factors leadings to C.
dificile infection in an individual patient are many, involving
the frequent administration of antibacterial chemotherapy in
such patients (Bartlett, 1979), gastrointestinal toxicity of anti-
neoplastic chemotherapy (Miller & Koornhof, 1984; Fain-
stein et al., 1981), and possibly environmental exposure to
the microorganism (Heard et al., 1988; Kim et al., 1981). The
clinical significance of treatment associated diarrhoea was
evaluated in the homogenous cohort of patients with disse-
minated germ cell cancer requiring intensive chemotherapy,
and C. difficile infection was found in a high proportion of
such episodes.
Materials and methods
During a period of 24 months a prospective, consecutive
study of the bacteriology of diarrhoea was done in patients
with disseminated germ cell cancer treated with high-dose
cisplatin, etoposide and bleomycin in cycles every 3rd week
(Daugaard & R0rth, 1986). The patients were treated in the
same department throughout the study. Twenty-five patients
were treated for a total of 90 series of chemotherapy (one
patient died after two cycles ofpneumococcal septicaemia, 15
patients had three cycles, six patients had four cycles, one
patient had five cycles, one patient had six cycles and one
patient had eight cycles). All patients received ketoconazole
200 mg daily from day six after chemotherapy and through-
out the leukopenic phase (< 1.0 x 109 leukocytes/l). No pro-
phylactic antibacterial therapy was given. During febrile
episodes (>38.5°C rectally) while leukopenic, the patients
were given empiric treatment with cefotaxime 2 g q 8 h or
other agents according to microbiological findings. In 77% of
the series the patients were leukopenic for a median of 6 days
(range 1-16 days). In patients with diarrhoea faecal speci-
mens were cultured for Clostridium difficile and for other
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pathogenic microorganisms as described previously (Tvede &
Rask-Madsen, 1989). Toxin production from C. difficile was
confirmed by cytotoxicity ofMcCoy cells after incubation for
24 h. Faecal specimens were analysed every other day during
diarrhoea episodes.
Results
During 90 cycles of cytotoxic chemotherapy in a homo-
genous cohort of patients with cancer requiring intensive
treatment clinical significant episodes of diarrhoea were pre-
sent in 31 cycles (34%) in 21 patients. In 14 of these episodes
(45%) a culture of Clostridium difficile was made from faecal
specimens. All isolates were toxin producing. In addition
there was six episodes in which Staphylococcus aureus was
cultured (one in combination with C. difficile), and one with
Pseudomonas aeruginosa. In no instance were other enteric
pathogens, i.e. Salmonella, Shigella, Vibrio, Y. enterocolitica
or Campylobacter jejuni/coli, found. Four patients had one
episode of C. dificile diarrhoea, two patients had two epis-
odes separated by negative cultures and absence of clinical
symptoms for more than 4 weeks, and two patients had three
episodes each. Distribution of C. difficile isolation through-
out the study period was without identifiable clusters. The
numbers of patients affected in the four half-year periods of
the study were three, one, two and two with a total of six,
two, three and three episodes of C. difficile associated diarr-
hoea, respectively.
The incidence of C. difficile isolation was 8% (2/25
patients) in the first cycle of chemotherapy, 12% (3/25
patients) in the second cycle, 20% (5/24 patients) in the third
cycle and 33% (3/9 patients) in the fourth cycle. In seven
episodes the patients had positive culture of C. difficile during
the first or second day of neutropenia, whereas in 7 episodes
the patients had positive cultures later during the neutropenic
period.
Two episodes of C. difficile diarrhoea were associated with
bacteraemia with other pathogens. During 90 cycles a total
of 14 bacteraemia episodes were observed. The frequency of
C. difficile in bacteraemic patients (2/14 = 14%) was not
statistically significant from C. difficile in non-bacteraemic
patients (12/76 = 16%), P> 0.05, Chi-square test. In seven
episodes the isolation of C. difficile from faecal specimens
was done on the same day as emperic treatment with cefotax-
ime was initiated, whereas in seven episodes antibacterial
chemotherapy had been administered before C. dificdile-assoc-
iated diarrhoea was diagnosed. Three cases were treated with
metronidazole, six cases with oral vancomycin, whereas no
treatment against C. difficile was given in the remaining five
eposides. In all patients the diarrhoea disappeared.
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Discussion
The contribution of Clostridium difficile as a cause of diarr-
hoea in patients with malignant diseases as reported by
others (Cudmore et al., 1982; Morris et al., 1984; Miller &
Koornhof, 1984; Rampling et al., 1985; Heard et al., 1988)
was confirmed by the present study. However, most reports
have dealt with description of single patients (Cudmore et al.,
1982; Miller & Koornhof, 1984; Rampling et al., 1985;
Fainstein et al., 1981), and only few studies have produced
estimation of the incidence/prevalence of this infection in a
prospectively manner (Morris et al., 1984; Heard et al.,
1988). Acute leukaemias were identified as increasing the risk
of infection (Morris et al., 1984; Heard et al., 1988), whereas
no data are available for patients with solid tumours.
The high incidence of C. difficile isolation in our patients
with treatment associated diarrhoea could suggest a nosoco-
mial transmission of infection, and it is difficult to exclude
this explanation as long as an efficient typing system of single
isolates is not available. However, the cases were evenly
distributed throughout the study period excluding any major
role of nosocomial transmission. The toxin production is
important in the pathogenesis of C. difficile infection, and
many of the systemic symptoms may be related to absorption
of the toxin. One of these manifestations may be pyrexia
(Cudmore et al., 1982; Miller & Koornhof, 1984) and it
appears to be justified to consider C. difficile in the evalua-
tion of fever of unknown origin in the immunocompromised
patient.
Many cytotoxic agents induce gastrointestinal mucosal
damage. It is possible that infection with toxin producing C.
difficile causes further mucosal damage, giving rise to the
possibility of development of bacteraemia with other species
of the gut flora. In patients with acute leukaemias Rampling
et al. (1985) observed an association of bacteraemia with C.
difficile diarrhoea, which was not found in our patients. This
may relate to the different cytotoxic drugs used, as primarly
antimetabolites have been connected with gastrointestinal
toxicity, while the role of cisplatin, etoposide and bleomycin
have been investigated less intensively. In one study of lung
cancer patients the combination of standard-dose cisplatin
and etoposide caused several diarrhoea in 8% of the patients
compared to 0% of patients treated with etoposide and
ifosfamide (Wolf et al., 1987).
It is well established that prior exposure to antibacterial
chemotherapy is associated with increased risk of C. difficile
diarrhoea (Bartlet, 1979). In the present study seven eposides
with C. difficile occurred on the same day as start of empiric
cefotaxime for fever in patients with neutropenia, which
makes it unlikely that this could be causally related. In the
seven other episodes it was difficult to distinguish between
cytotoxic or antibacterial therapy as the initiating factor, but
it should be noted that cytotoxic drugs by themselves have
been suggested as precipitating C. difficile diarrhoea (Cud-
more et al., 1982; Miller & Koornhof, 1984; Fainstein et al.,
1981).
In conclusion, clinical important episodes of diarrhoea are
found in many patients given intensive cytotoxic
chemotherapy for advanced cancer, and in a high proportion
of these cases C. difficile could be isolated from faecal speci-
mens. As C. difficile infection may aggravate the clinical
condition and possibly dispose to bacteraemia in these
patients, the demonstration of C. difficile should be sought
for and appropriate treatment initiated when isolated.
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